United States Prostate Cancer Consensus Conference 2025

Considerations for Patient Selection and Imaging in PSMA-Targeted Therapy - Tanya Dorff & Julie Graff

Managing mHSPC with ADT and ARPI Therapy - Brian Chapin & David Morris

Diagnostic and Staging Approaches for Localized Neuroendocrine Prostate Cancer - Joshua Lang & Rana McKay

Treatment Sequencing and PARP Inhibitors in Advanced Prostate Cancer - Tanya Dorff

Discussion on the Use of Bone Modifying Agents in Metastatic Prostate Cancer - Tian Zhang and Evan Yu

Discussion on Patient Selection for Radioligand Therapy in Prostate Cancer - Oliver Sartor and Daniel Petrylak

Discussion on Treatment Sequencing for mCRPC After Progression on ADT, ARPI, and Docetaxel - Phillip Kuo & Oliver Sartor

Considerations for Patient Selection in PSMA Radioligand Therapy - Scott Tagawa & Alan Bryce

Gene-Specific Analysis of PARP Inhibitor Response in Prostate Cancer - Pedro Barata

Association Between SPOP Gene Mutations and Response to Androgen Therapy - Neeraj Agarwal & Daniel Petrylak

Examining the Role of Tumor Suppressor Gene Loss and Chemotherapy Intensification in Prostate Cancer - Matthew Smith

Discussion on Biomarker Selection for Immunotherapy in Prostate Cancer - Michael Carducci & Tian Zhang

Consensus Recommendations for PSMA PET Imaging and Treatment Strategies in Biochemical Recurrence - Mary-Ellen Taplin

Consensus Recommendations for PARP Inhibitor Use in Metastatic Prostate Cancer - Michael Carducci

Consensus Recommendations for ARPI Sequencing and Radioligand Therapy in mCRPC - Michael Morris

Consensus Recommendations for PSMA PET Imaging in Metastatic Prostate Cancer - Tanya Dorff

This webpage is equally supported by AstraZeneca and Bayer Pharmaceuticals. Neither company is involved in content development or review, and the views expressed are those of the physician and/or patient contributors.